Zura Bio Limited

NasdaqCM ZURA

Zura Bio Limited Free Cash Flow Yield on January 14, 2025

Zura Bio Limited Free Cash Flow Yield is NA on January 14, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Zura Bio Limited 52-week high Free Cash Flow Yield is NA on January 14, 2025, which is NA below the current Free Cash Flow Yield.
  • Zura Bio Limited 52-week low Free Cash Flow Yield is NA on January 14, 2025, which is NA below the current Free Cash Flow Yield.
  • Zura Bio Limited average Free Cash Flow Yield for the last 52 weeks is NA.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
NasdaqCM: ZURA

Zura Bio Limited

CEO Mr. Robert Lisicki
IPO Date March 21, 2023
Location United States
Headquarters 4225 Executive Square
Employees 14
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

StockViz Staff

January 15, 2025

Any question? Send us an email